Jeena Sikho Lifecare Limited reported a 29% year-on-year increase in revenue from operations to ₹224.4 crore for the quarter ended June 30, 2026 (Q1 FY27), compared to ₹174.3 crore in the corresponding period of the previous fiscal year. The growth was primarily driven by strong performance in its private-pay Panchakarma hospitalisation segment and a rapid expansion in its digital medicine channel.

The company’s strategic shift towards private-pay patients is evident in the operational data. Private-pay inpatient department (IPD) admissions rose 33% to 11,500, contributing ₹84.8 crore to revenue, a 26% increase year-on-year. This robust volume growth helped offset a significant contraction in government-panel IPD revenue, which fell 67% to ₹5.2 crore from ₹15.5 crore in Q1 FY26. Consequently, the share of government-panel revenue in total revenue dropped from 8.9% to 2.3%.

Revenue Breakdown by Channel

Healthcare services revenue increased 13% to ₹106.0 crore. While private-pay IPD alone would have shown a 26% growth rate, the blended services growth was moderated by the decline in government-panel activity. On a fully blended basis including day-care but excluding diagnostics and consultation, total IPD volume grew 16.9% while total IPD revenue rose 8.8%.

What the Numbers Show

The divergence between headline revenue growth and services revenue growth highlights a deliberate mix shift. Private-pay IPD admissions grew 33%, yet blended healthcare services revenue expanded only 13%. This gap is explained by the collapse in government-panel revenue, which declined by ₹10.3 crore. Management has flagged government-panel schemes as carrying slower collections, implying weaker cash conversion. By reducing exposure to this segment, the company is trading top-line acceleration in the services vertical for improved earnings quality and cash flow predictability, consistent with its stated strategy of remaining predominantly private-pay.

Acharya Manish Grover, Managing Director and Chairman, noted that the quarter reflected continued scale-up across the integrated healthcare and medicines platform. He emphasized that the company remains focused on disciplined centre economics, patient outcomes, and sustainable profitable growth as the network expands.

Jeena Sikho Lifecare has published six additional clinical case studies in peer-reviewed journals, further expanding its portfolio of evidence-based Ayurvedic research. The disclosures were made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on August 18, 2026.

This update follows the company's previous disclosure on August 17, 2026, where it reported seven case studies published in Ayushdhara and the International Research Journal of Ayurveda & Yoga. The latest publications appear in the Academia Journal of Medicine and Prakriti - The International Multidisciplinary Research Journal.

New Research Publications

The newly published studies were authored by medical professionals associated with the company, including Managing Director Manish Grover, senior consultants, and Ayurvedic experts. The research covers a range of conditions, with a notable focus on renal health and reproductive medicine.

The inclusion of multiple studies on kidney disease—covering both chronic and acute phases, as well as specific Ayurvedic concepts like Vrikka Roga and Mutravaha Srotas Dushti—highlights the company's specialized clinical experience in nephrology. Additionally, the study on Vandhyatva (infertility) expands the scope of their documented therapeutic interventions into reproductive health.

Strategic Implications

These publications serve to validate the company’s clinical protocols through peer-reviewed channels. By documenting outcomes for high-prevalence chronic conditions like kidney disease, as well as specific issues like piles and infertility, Jeena Sikho Lifecare reinforces its brand positioning as a provider of specialized, research-backed Ayurvedic care. The continued involvement of the Managing Director in authoring these studies signals strong leadership engagement in the company’s scientific and educational initiatives.

The cumulative effect of publishing 13 case studies within a single day underscores a concerted effort to build a robust body of clinical evidence supporting the company's treatment methodologies.